Headache Cooperative of New England 32nd Annual Stowe Headache Conference (Hybrid) - April 1 - 2, 2022

Claiming Credit

Thank you for participating in this program. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to complete the evaluation and claim your credit on the following page.

This program is a comprehensive overview of the current state of Headache Medicine.  This program focuses on an in-depth consideration of specific headache and facial pain topics, with a focus on the most common primary and secondary headache disorders. It is designed to provide more clinically useful detail than a typical continuing medical education program in which a single lecture on headache would be included among lectures on other topics.   The course is designed to enable attendees to enhance their clinical and research skills by gaining knowledge in the latest concepts concerning diagnosis, treatment, and mechanisms of the primary and secondary headache disorders.

Target Audience

This program is designed to educate practitioners who have an interest in the diagnosis and management of headache disorders. These include neurologists, primary care providers, dentists, psychologists, nurse practitioners, physician assistants, physical therapists, and other health care providers with an interest in Headache Medicine. 

Learning Objectives

At the conclusion of this activity, the participants will be able to:                                                   

  1. Describe the classification, diagnosis, and treatment alternatives for the common primary headache disorders.
  2. Conceptualize prodrome, aura and postdrome phases in migraine.
  3. Recognize "dangerous" secondary headaches
  4. Plan appropriate acute/abortive, preventive, and rescue treatment of migraine and the trigeminal autonomic cephalalgias (TACS).
  5. Explain the rationale for the use of monoclonal antibodies in migraine prevention and compare the various CGRP inhibiting mAbs.
  6. Describe the role of gepants and ditans in the acute and preventive treatment of migraine.
  7. Differentiate the various neuromodulation approaches in the primary headache disorders.
  8. Examine the disparities in headache care in the United States.
  9. Describe the functional and structural brain changes in migraine.
  10. Discuss the role of the hypothalamus in migraine pathophysiology
  11. Explain the circadian timing system in relation to cluster headache as well as other head pain states.
  12. Discuss the role of fear avoidance in migraine and plan effective behavioral interventions.
  13. Plan interventions for refractory chronic migraine
Course summary
Available credit: 
  • 15.75 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 15.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 15.75 ANCC
  • 15.75 Participation
Course opens: 
04/01/2022
Course expires: 
04/02/2023
Rating: 
0
Committee member(s)

Jessica Duplin, RN, MSN

has a financial relationship (Independent contractor) with Impel NeuroPharmacy, Inc;.
has a financial relationship (Independent contractor) with BioDelivery Sciences International, Inc;.

DANIELLE WARD

has no relevant financial relationships to disclose at this time.

Thomas Ward, MD

has a financial relationship (Other) with AEON;.
Moderator(s)

Thomas Ward, MD

has a financial relationship (Other) with AEON;.

Randall Weeks, Ph.D. Clinical Psychology

has no relevant financial relationships to disclose at this time.
Planner(s)

Mark Burish, MD PhD

has a financial relationship (Financial Support) with Praxis Precision Medicines ;.
has a financial relationship (Financial Support) with Beckley Psytech limited ;.

Jessica Duplin, RN, MSN

has a financial relationship (Independent contractor) with Impel NeuroPharmacy, Inc;.
has a financial relationship (Independent contractor) with BioDelivery Sciences International, Inc;.

DANIELLE WARD

has no relevant financial relationships to disclose at this time.
Speaker(s)

Sait Ashina, Sait Ashina, MD, FAHS

has a financial relationship (Other) with Eli Lilly and Company;.
has a financial relationship (Other) with Theranica;.
has a financial relationship (Other) with Impel NeuroPharma ;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Biohaven;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Other) with Percept;.

Rami Burstein, PhD

has a financial relationship (Grant Or Contract) with Eli Lilly;.
has a financial relationship (Stock Options) with Percept;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Grant Or Contract) with Allergan/AbbVie;.
has a financial relationship (Stock Options) with Theranica;.
has a financial relationship (Professional Services) with Biohaven;.
has a financial relationship (Grant Or Contract) with NIH;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with Neurolief;.
has a financial relationship (Grant Or Contract) with TEVA;.
has a financial relationship (Intellectual Property Other) with Allay;.
has a financial relationship (Professional Services) with Revance;.

Andrea Harriott, MD PhD

has a financial relationship (Other) with Abbvie;.

Morris Levin, MD Professor, UCSF Dept of Neurology

has a financial relationship (Independent contractor) with BDNI;.
has a financial relationship (Independent contractor) with Biohaven;.
has a financial relationship (Independent contractor) with Abbvie;.

Elizabeth Loder, MD, MPH

has no relevant financial relationships to disclose at this time.

peter mcallister, MD, FAAN

has a financial relationship (Professional Services) with biohaven;.
has a financial relationship (Professional Services) with BDSI;.
has a financial relationship (Professional Services) with amgen;.
has a financial relationship (Professional Services) with Impel;.
has a financial relationship (Professional Services) with teva;.
has a financial relationship (Professional Services) with Lilly;.

Stephanie Nahas, MD, MSEd, FAHS, FAAN

has a financial relationship (Independent contractor) with Allergan/AbbVie;.
has a financial relationship (Independent contractor) with Biohaven;.
has a financial relationship (Independent contractor) with Nesos Corp (formerly Vorso Corp);.
has a financial relationship (Other) with Eli Lilly;.
has a financial relationship (Independent contractor) with Alder/Lundbeck;.
has a financial relationship (Independent contractor) with BioDelivery Sciences;.
has a financial relationship (Independent contractor) with Impel;.
has a financial relationship (Other) with Amgen/Novartis;.
has a financial relationship (Independent contractor) with Axsome;.
has a financial relationship (Independent contractor) with Fenix Group International;.
has a financial relationship (Other) with Allergan/AbbVie;.
has a financial relationship (Independent contractor) with Amgen/Novartis;.
has a financial relationship (Independent contractor) with Eli Lilly;.
has a financial relationship (Independent contractor) with Teva;.
has a financial relationship (Other) with Teva;.

Ronald Purdy

has no relevant financial relationships to disclose at this time.

Alan Rapoport, M.D.

has a financial relationship (Independent contractor) with Cala Health;.
has a financial relationship (Independent contractor) with XOC;.
has a financial relationship (Independent contractor) with Biohaven;.
has a financial relationship (Independent contractor) with Theranica;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Independent contractor) with Teva;.
has a financial relationship (Independent contractor) with Lundbeck;.
has a financial relationship (Independent contractor) with AbbVie;.
has a financial relationship (Independent contractor) with Satsuma;.
has a financial relationship (Independent contractor) with Zosano;.

Krishnamurthy Ravishankar, MD

has no relevant financial relationships to disclose at this time.

Paul Rizzoli, MD

has no relevant financial relationships to disclose at this time.

lawrence robbins, MD

has no relevant financial relationships to disclose at this time.

Elizabeth Seng, Ph.D.

has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Click Therapeutics LLC;.
has a financial relationship (Professional Services) with GlaxoSmithKline;.

Robert Shapiro, MD, PhD, Professor of Neurological Sciences, University of Vermont.

has a financial relationship (Grant Or Contract) with Eli Lilly;.
has a financial relationship (Other) with Lundbeck;.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and the Headache Cooperative of New England (HCNE). 

Boston University School of Medicine designates this live activity for a maximum of 15.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly-provided by Headache Cooperative of New England.

Contact Hours: 11 of which 3 are pharmacology credit worthy.

Available Credit

  • 15.75 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 15.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 15.75 ANCC
  • 15.75 Participation

Educational Grants

This activity is supported by an educational grant from AbbVie.

This activity is supported by educational funding provided by Amgen

This activity is supported by an educational grant from Lilly.

Please login or register to take this course.